Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 490

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 490
---
 $4.7 million net proceeds from the Legacy TuHURA private placement in July 2024, and $2.0 million proceeds from stock options and warrants exercises, offset by $4.4 million in merger transaction costs and net liabilities attributable to Kintara. For the year ended December 31, 2023, net cash provided by financing activities was $2.7 million, which primarily consisted of net proceeds from convertible notes issued as part of the TuHURA Note Financing. Funding Requirements TuHURA expects to incur additional costs associated with operating as a public company. In addition, TuHURA anticipates that it will need substantial additional funding in connection with its continuing operations. TuHURA believes that its existing cash and cash equivalents, together with the estimated net proceeds from the TuHURA Note Financing, will be sufficient to meet its anticipated cash requirements through late into the fourth quarter of 2025. This excludes the cash needed to complete the Mergers, as the Merger Agreement provides that it is a condition to the closing of the Mergers that TuHURA complete a financing transaction resulting in net proceeds of no less than $35 million, and there is no assurance that TuHURA will be able to complete such a financing transaction. However, TuHURA’s forecast of the period through which its financial resources will be adequate to support its operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Management based projections of operating capital requirements on TuHURA’s current operating plan, which includes several assumptions that may prove to be incorrect, and TuHURA may deplete its available capital resources sooner than management expects. TuHURA’s future capital requirements will depend on many factors, including:

| • |     | the initiation, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of 
 IFx-Hu2.0, IFx-Hu3.0 and any other future product candidates;                                                     |

| • |     | the costs associated with hiring additional personnel and consultants as TuHURA’s preclinical and clinical 
 activities increase;                                                                                       |

| • |     | the outcome, timing and costs of seeking regulatory approvals; |

| • |     | the cost of manufacturing IFx-Hu2.0 and                                                                                                     
 IFx-Hu3.0 and future product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization; |

| • |     | the emergence of competing therapies and other adverse